Nitrosative™ and nitroscience™ are trademarks of Pharmahungary.
Pharmahungary runs some in-house R&D projects for the diagnosis and therapy of cardiovascular and metabolic diseases, currently focusing e.g. on the development of inhibitors of peroxynitrite againts nitrosative stress (nitroscience™ project) and its downstream cellular target matrix metalloproteinases (MMPharma™ project) for pathologies involving ischemia/reperfusion injury such as ischemic heart disease. Pharmahungary intends to outlicense its new technologies.